Back to Search
Start Over
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
- Source :
-
Leukemia [Leukemia] 2024 Apr; Vol. 38 (4), pp. 918-922. Date of Electronic Publication: 2024 Feb 17. - Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 1476-5551
- Volume :
- 38
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Leukemia
- Publication Type :
- Editorial & Opinion
- Accession number :
- 38368440
- Full Text :
- https://doi.org/10.1038/s41375-024-02180-3